SEC Contract Filing

Filing Date: 2021-04-02

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d147373dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SHARE REPURCHASE AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This SHARE REPURCHASE AGREEMENT, dated as of March&nbsp;31, 2021 (this &#147;<U>Agreement</U>&#148;), is by and between by and between
Bristol-Myers Squibb Company, a Delaware corporation (&#147;<U>BMS</U>&#148;), and Agios Pharmaceuticals, Inc., a Delaware corporation (the &#147;<U>Purchaser</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, BMS
desires for the BMS Entities (as defined below) to sell shares of common stock, par value $0.001 per share, of the Purchaser (&#147;<U>Common Shares</U>&#148;) to the Purchaser, and the Purchaser desires to purchase Common Shares from the BMS
Entities, on the terms and conditions set forth in this Agreement (the &#147;<U>Repurchase Transaction</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in
consideration of the agreements set forth below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SALE AND
PURCHASE OF COMMON SHARES </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchase</U>. Subject to the terms and conditions of this
Agreement, including <U>Section</U><U></U><U>&nbsp;1.3</U>, BMS shall cause the BMS Entities to sell, assign, transfer, convey and deliver to the Purchaser, and the Purchaser shall purchase, acquire and accept from the BMS Entities, an aggregate of
7,121,658 Common Shares (the &#147;<U>Shares</U>&#148;) on such date (the &#147;<U>Closing Date</U>&#148;) as is mutually agreed by the parties in writing by 5 pm on April&nbsp;2, 2021; <U>provided</U>, <U>however</U>, that the Closing Date shall
not be deferred beyond April&nbsp;15, 2021; <U>provided</U>, <U>further</U>, that, if after the execution of this Agreement and prior to the Closing Date, any of the following events specified in clauses (1), (2), (3) or (4)&nbsp;below shall have
occurred in such a manner that shall make it impracticable for either party to consummate the transactions contemplated by this Agreement on the first proposed Closing Date, then the Closing Date shall be deferred to the first date on which none of
the following events specified in clauses (1), (2), (3) or (4)&nbsp;below shall be in effect or, if earlier, when the parties shall be able to consummate the transactions contemplated by this Agreement (but in no event shall the Closing Date be
deferred beyond April&nbsp;15, 2021): (1) trading generally have been suspended or materially limited on the Nasdaq Stock Market; (2)&nbsp;trading of any securities issued or guaranteed by the Purchaser have been suspended on any exchange or in any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (3)&nbsp;a general moratorium on commercial banking activities have been declared by federal or New York State authorities; or (4)&nbsp;there have
occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, which makes it impracticable to consummate the transactions contemplated by this Agreement.
The purchase price for the Shares shall be equal to $344,535,309.59 (the &#147;<U>Purchase Price</U>&#148;), or approximately $48.3785 per share. </P>
</DIV></Center>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing</U>. On the Closing Date, BMS shall
deliver or cause to be delivered to the Purchaser all of the rights, titles and interests of Celgene Corporation, Celgene Switzerland LLC, Celgene European Investment Company LLC, and Celgene Alpine Investment Co., LLC (collectively, the
&#147;<U>BMS Entities</U>&#148;) and of BMS in and to the Shares by delivery of a duly executed stock powers or other instruments of assignment and, in the case of Shares represented by one or more physical certificates, delivery of such
certificates. On the Closing Date, the Purchaser shall pay to each BMS Entity its portion of the Purchase Price in cash by wire transfer of immediately available funds in accordance with the wire transfer instructions to be provided by BMS to the
Purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding</U>. The Purchaser and any other applicable withholding agent shall be
entitled to deduct and withhold from any amounts paid or payable pursuant to this Agreement such amount as the Purchaser or such other applicable withholding agen